Human umbilical cord blood-derived mesenchymal stem cells

BIOLOGICAL3 trials

Sponsors

Medipost Co Ltd., Samsung Medical Center, Gangnam Severance Hospital

Conditions

Acute LeukemiaAllogeneic Hematopoietic TransplantDisorder Related to TransplantationGVHDGraft-Versus-Host DiseaseRecessive Dystrophic Epidermolysis Bullosa

Phase 1

Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation

CompletedNCT00823316

Medipost Co Ltd.Acute Leukemia

Start: 2008-08-31End: 2010-02-28Updated: 2012-04-23

Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease

Samsung Medical CenterAllogeneic Hematopoietic Transplant, Disorder Related to Transplantation, Graft-Versus-Host Disease +1

Start: 2012-01-31End: 2012-12-31Target: 30Updated: 2012-03-16

Safety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB

CompletedNCT04520022

Gangnam Severance HospitalRecessive Dystrophic Epidermolysis Bullosa

Start: 2016-10-13End: 2020-01-10Updated: 2020-08-20

Related Papers

Intravenous allogeneic umbilical cord blood–derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

JCI Insight2021-01-2449 citations